Function of regulatory T-cells improved by dexamethasone in Graves' disease

European Journal of Endocrinology

Volumn 166, Issue 4, 2012, Pages 641-646

  Hu, Yun ^a   Tian, Wei ^a   Zhang, Ling Ling ^a   Liu, Hao ^a   Yin, Guo Ping ^a   He, Bang Shun ^b   Mao, Xiao Ming ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; BLOOD; CD4+ CD25+ T LYMPHOCYTE; CD4+ CD25- T LYMPHOCYTE; CELL COUNT; CELL CULTURE; CELL ISOLATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; FEMALE; GENE EXPRESSION; GRAVES DISEASE; HUMAN; IMMUNOMAGNETIC SEPARATION; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH2 CELL;

ADULT; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GRAVES DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; PRIMARY CELL CULTURE; T-LYMPHOCYTES, REGULATORY;

EID: 84859400124     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0879     Document Type: Article

References (28)

1. + naturally occurring regulatory T cells and not lymphopenia play a role in the pathogenesis of iodide-induced autoimmune thyroiditis in NOD-H2h4 mice. Journal of Autoimmunity 2007 29 195-202. (doi:10.1016/j.jaut.2007.07.008)
2. + regulatory T cells in a mouse model. Endocrinology 2006 147 2417-2422. (doi:10.1210/en.2005-1024)
3. +regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. Journal of Immunology 2011 186 4734-4743. (doi:10.4049/jimmunol.0904135)
4. McLachlan SM, Nagayama Y, Pichurin PN, Mizutori Y, Chen CR, Misharin A, Aliesky HA & Rapoport B. The link between Graves' disease and Hashimoto's thyroiditis: a role for regulatory T cells. Endocrinology 2007 148 5724-5733. (doi:10.1210/en.2007-1024)
5. Romagnani S. Regulatory T cells: which role in the pathogenesis and treatment of allergic disorders? Allergy 2006 61 3-14. (doi:10.1111/j.1398-9995. 2006.01005.x)
6. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA & Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. Journal of Immunology 1986 136 2348-2357. (Pubitemid 16136806)
7. Mosmann TR & Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology 1989 7 145-173. (doi:10.1146/annurev.iy.07.040189.001045)
8. Nicholson LB & Kuchroo VK. Manipulation of the Th1/Th2 balance in autoimmune disease. Current Opinion in Immunology 1996 8 837-842. (doi:10.1016/S0952-7915(96)80013-6)
9. Inukai Y, Momobayashi A, Sugawara N & Aso Y. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. European Journal of Endocrinology 2007 156 623-630. (doi:10.1530/EJE-07-0019)
10. Abraham P, Avenell A, Park CM, Watson WA & Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. European Journal of Endocrinology 2005 153 489-498. (doi:10.1530/eje.1.01993)
11. Weetman AP. Graves' disease. New England Journal of Medicine 2000 343 1236-1248. (doi:10.1056/NEJM200010263431707)
12. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA & Aanderud S. Graves' disease: drug regimens and predictors of outcome. European Journal of Endocrinology 2002 147 583-589. (doi:10.1530/eje.0.1470583)
13. Mao XM, Li HQ, Li Q, Li DM, Xie XJ, Yin GP, Zhang P, Xu XH, Wu JD, Chen SW & Wang SK. Prevention of relapse of Graves' disease by treatment with an intrathyroid injection of dexamethasone. Journal of Clinical Endocrinology and Metabolism 2009 94 4984-4991. (doi:10.1210/jc.2009-1252)
14. Wiersinga WM, Smit T, Schuster-Uittenhoeve AL, van der Gaag R & Koornneef L. Therapeutic outcome of prednisone medication and of orbital irradiation in patients with Graves' ophthalmopathy. Ophthalmologica 1988 197 75-84. (doi:10.1159/000309924)
15. Lacka K, Manuszewska E, Korczowska I & Lacki JK. The effect of methylprednisolone pulse treatment on cytokine network in Graves ophthalmopathy. Current Eye Research 2007 32 291-297. (doi:10.1080/02713680601186698)
16. + CD25 high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Annals of the Rheumatic Diseases 2006 65 1512-1517. (doi:10.1136/ard.2005.049924)
17. + regulatory Tcells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. European Journal of Haematology 2007 79 310-316. (doi:10.1111/j.1600-0609.2007.00917.x)
18. Marazuela M, García-López MA, Figueroa-Vega N, de la Fuente H, Alvarado-Sánchez B, Monsiváis-Urenda A, Sánchez-Madrid F &González-Amaro R. Regulatory T cells in human autoimmune thyroid disease. Journal of Clinical Endocrinology and Metabolism 2006 91 3639-3646. (doi:10.1210/jc.2005-2337)
19. Dang S & Shi BY. Variation of CD4 CD25 regulatory T cells in patients with Graves' disease. Chinese Journal of Endocrinology and Metabolism 2007 23 253-256.
20. Mellman I & Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001 106 255-258. (doi:10.1016/S0092-8674(01) 00449-4)
21. Noh J, Choi WS, Noh G & Lee JH. Presence of Foxp3-expressing CD19(+)CD5(+) B cells in human peripheral blood mononuclear cells: human CD19(+)CD5(+)Foxp3(+) regulatory B cell (Breg). Immune Network 2010 10 247-249. (doi:10.4110/in.2010.10.6.247)
22. Engelmann P, Farkas K, Kis J, Richman G, Zhang Z, Liew CW, Borowiec M, Niewczas MA, Jalahej H & Orbán T. Characterization of humaninvariantnatural killerTcells expressing FoxP3. International Immunology 2011 23 473-484. (doi:10.1093/intimm/dxr040)
23. Pallardy M & Biola A. Induction of apoptosis in lymphocytes by glucocorticoids: between physiology and pharmacology. Comptes Rendus des Séances de la Société de Biologie et de Ses Filiales 1998 192 1051-1063.
24. Grbović L & Radenković M. Therapeutic use of glucocorticoids and immunosuppressive agents. Srpski Arhiv za Celokupno Lekarstvo 2005 133 (Suppl 1) 67-73.
25. Kang Y, Xu L, Wang B, Chen A & Zheng G. Cutting edge: immunosuppressant as adjuvant for tolerogenic immunization. Journal of Immunology 2008 180 5172-5176.
26. + regulatory T cells in nonlymphopenic hosts. Journal of Leukocyte Biology 2007 82 1053-1061. (doi:10.1189/jlb.0407227)
27. Ward LS & Fernandes GA. Serum cytokine levels in autoimmune and non-autoimmune hyperthyroid states. Brazilian Journal of Medical and Biological Research 2000 33 65-69. (doi:10.1590/S0100-879X2000000100009)
28. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A & Serio M. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. American Journal of Pathology 2002 161 195-206. (doi:10.1016/S0002-9440(10) 64171-5)